WuXi XDC announces mechanical completion of Singapore site

The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint

The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.

Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability

InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services

India exports US$ 4,961 million pharmaceutical during April–May 2025: Pharmexcil

Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery

INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease

Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients

Lupin carves out LupinLife Consumer Healthcare